474 related articles for article (PubMed ID: 22871192)
1. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
Ahrens I; Bode C
Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192
[TBL] [Abstract][Full Text] [Related]
2. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
3. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Galanis T; Merli GJ
Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
Paikin JS; Manolakos JJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
ROCKET AF Study Investigators
Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
9. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
10. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
11. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Martínez-Rubio A; Dan GA; Kaski JC
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
15. [Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
Simonyi G; Medvegy M
Ideggyogy Sz; 2012 Nov; 65(11-12):365-8. PubMed ID: 23289170
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
17. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of embolic heart complications in atrial fibrillation: possibilities of using rivaroxaban].
Iavelov IS
Ter Arkh; 2013; 85(12):119-26. PubMed ID: 24640681
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Carter NJ; Plosker GL
Drugs; 2013 May; 73(7):715-39. PubMed ID: 23677801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
